Hana Tran’s Post

🩵 Disease Background – Why Dry Eyes Matter 👁️ Dry Eye Syndrome (DES) is a multifactorial disease that affects the tear film and ocular surface. It can be caused by aging, screen overuse, medications, or environmental stress. ⚠️ Disruption of the corneal epithelium leads to: – 🔥 Inflammation – 😣 Irritation and burning sensation – 🌫️ Blurred vision – 🩹 Delayed healing and increased infection risk 💧 Protecting and restoring the corneal barrier is essential for long-term eye health. 🔬 Clinical Evidence – Proven by Science 📊 A randomized, double-blind, controlled clinical study investigated the efficacy of Dexpanthenol in managing dry eyes, showing: ✅ Improved corneal epithelial permeability – a critical marker in ocular surface recovery ✅ Significant symptom relief within 2 weeks, with marked improvement by week 6 ✅ Better healing outcomes compared to placebo or standard artificial tears ✅ Enhanced tear film stability and moisture retention 👩⚕️ Patients using Dexpanthenol-containing drops (such as GELB5 Eye) experienced: ✨ Fewer dry spots ✨ Reduced ocular surface damage ✨ Higher comfort and satisfaction 💧 Advanced Formulation Formulated with Carbomer for prolonged contact time and Liquidshield™ Technology for sustained hydration. 🚫 No preservatives 🚫 No irritation ✅ Suitable for long-term or sensitive use 🌟 Choose GELB5 Eye – where clinical science meets daily comfort and healing.

Today, November 14, is the World Diabetes Day. Diabetic retinopathy affects lives of millions of people. It is one of the most common complications of diabetes and among the leading causes of blindness holding the first place in working-age adults. During the early stages diabetic retinopathy remains often without symptoms and can therefore go unnoticed. Regular and efficient screenings are crucial for saving the vision of the patients with diabetes. Early detection of the signs of the pathology can empower the patients to change their lifestyle in order to gain better control of the disease improving the quality of life. Modern solutions provide diabetologists, endocrinologists, and general practitioners with advanced tools for a holistic view of patients’ health, including eye health. With the help of instant screening results, they can identify the patients in need of specialized care and refer them to the ophthalmologist for treatment. The seamless collaboration between the screener and the ophthalmologists can lead to better outcomes and prevent blindness – keeping the wonderful world visible for their patients. Read more: https://hubs.la/Q03SLSWy0

Abstract: The Terrain-Level Determinants of Ischemic Stroke — An ALH–eGFR Framework for Precision Prevention While ischemic stroke is classically categorized by mechanism—embolism, thrombosis, dissection, or small-vessel disease—these visible outcomes emerge from deeper, measurable changes in the body’s terrain. In this integrated framework, stroke risk is redefined not as an isolated vascular event but as the endpoint of cumulative terrain erosion. Declining eGFR (estimated glomerular filtration rate), endothelial microinjury, oxidative stress, dehydration, and allostatic overload together alter plasma viscosity, shear dynamics, and mitochondrial resilience—conditions that silently prepare the vasculature for failure. Likewise, caregiving stress, malnutrition, and iatrogenic medication patterns accelerate inflammatory cascades and vascular fragility. The ALH Caregiver Index, paired with eGFR trajectories, identifies early inflection points where preventive interventions—hydration, oxygenation, rhythm regulation, cooling therapy, and caregiver education—can preserve neuronal integrity and reduce stroke incidence. This terrain-based model reframes prevention around upstream metrics of biological and behavioral health, bridging patient care, public health, and precision medicine.

PLEURAL EFFUSION :- • Pleural effusion is the abnormal accumulation of fluid in the pleural space, impairing gas exchange and lung expansion. It is classified as either:🔹 Transudative (Watery Fluid) :-• Caused by systemic factors (↑ hydrostatic or ↓ oncotic pressure)  • Common causes:     - Heart failure     - End-stage renal disease     - Liver cirrhosis with ascites  🔹 Exudative (Protein-Rich/Thicker Fluid) :-• Caused by local inflammation or malignancy  • Common causes:     - Malignancy     - Pulmonary embolism     - Tuberculosis  🔍 Signs & Symptoms :-• May be asymptomatic  • Dyspnea (SOB)  • Pleuritic chest pain  • ↓ Breath sounds or absent on auscultation  🧪 Diagnostic Tests :-• Chest X-ray, ultrasound  • Thoracentesis for fluid analysis  • Physical exam (↓ breath sounds, dull percussion)  💉 Treatment :-  • Thoracentesis  • Treat underlying cause (e.g., antibiotics)  💡 Nursing Interventions :-  • Monitor respiratory status, vital signs  • Position in High Fowler’s  • Administer O2 as needed  • Pain control  • Encourage deep breathing, incentive spirometry  📚 Client Education :-• Report worsening symptoms: SOB, cyanosis, bloody sputum⚠️ Complications :-• Pneumothorax  • Empyema  • Lung fibrosis  

To Physiatrists - Post 2 of 4: Neurogenic Bladder/Bowel Solutions Neurogenic incontinence is one of your most challenging complications—unpredictable, difficult to manage, and devastating for patient morale. Here's what the Curaco Carebidet does for neurogenic dysfunction: **The Complete System:** ✓ **Continuous Monitoring**: Sensors detect both urinary and fecal incontinence instantly—no matter how unpredictable ✓ **Immediate Response**: Automated cleaning begins within seconds of detection ✓ **Handles All Consistency**: Manages liquid, formed, or mixed stool from neurogenic bowel ✓ **Gentle Cleansing**: Adjustable water pressure respects sensitive skin and surgical sites ✓ **Complete Drying**: Warm air prevents moisture-related complications **Clinical outcomes for rehab patients:** • 63% reduction in hands-on hygiene care time • Significantly lower pressure ulcer development • Reduced UTI rates from immediate cleaning • Better therapy compliance (no embarrassment) • Improved patient motivation and mental health **Perfect for patients with:** • Spinal cord injury (complete or incomplete) • Stroke with bowel/bladder dysfunction • Multiple sclerosis • Parkinson's disease • Traumatic brain injury FDA 510(k)-exempt | CMS-recognized | Billable E2001/A9286 👉 Follow for rehabilitation innovations! 📅 See it in action: https://lnkd.in/gnjsUYzb Next: Real patient scenarios →

In addition to treating inflammation in patients with polymyalgia rheumatica (PMR), clinicians should include mobility and independence as explicit targets of care due to the associated functional decline in this population. A proposed function modification PMR model includes the following steps: 1. Assess and track functional performance in the clinic using feasible and prognostic measures (e.g., gait speed, 5-times sit-to-stand, and Short Physical Performance Battery). 2. Provide early education on the importance of staying active, with referral to physiotherapy as needed, to prescribe individualized progressive resistance training for girdle muscles, balance/coordination exercises, and aerobic conditioning—dosing tailored to disease status. Physiotherapists emphasize the value of physical therapy in supporting people with PMR. 3. Assess fracture risk, including pharmacologic interventions and fall-prevention strategies. These steps should run parallel to pharmacologic management, including glucocorticoids and glucocorticoid-sparing therapies, aiming for remission or low disease activity while optimizing daily function. *From: O’Brien AV, Sattui SE. From symptom amelioration to function modification: is it time to expand the treatment focus in polymyalgia rheumatica? Rheumatology (Oxford), 2025.  🔗https://lnkd.in/dBiuZr5i

Prof. Carel Le Roux reminds us that obesity is a relapsing disease with over 220 complications. Yet, unlike hypertension or diabetes, obesity has long lacked clear treatment targets, limiting the ability to deliver structured and effective care. Thanks to advances such as metabolic bariatric surgery and new medications like semaglutide and tirzepatide, achieving 20–25% weight loss is now possible. For the first time, this allows clinicians to set meaningful treatment targets, helping track progress, improve clinician–patient alignment, and integrate obesity care into a chronic disease model. Recent qualitative research also revealed five key factors influencing patient decisions in obesity treatment. The takeaway message is clear: Provide tailored, transparent information. Ask not only about weight-loss goals, but also about health gains and quality of life. Understand patients’ fears and support needs.

303/365 Studies suggesting that coffee/ caffeine intake is not associated with a higher risk of Atrial Fibrillation (AF) and may even be protective. Since you work in paediatric cardiac nursing and post educational content, here’s a breakdown of the evidence — what’s solid, what to caveat, and what this might mean. ✅ What the evidence says 🧩Observational/epidemiologic studies ⭕A meta-analysis found that increased coffee consumption was associated with a small reduction in incident AF risk. For example, one cup/day increment → ~2% lower risk (RR = 0.98, 95% CI 0.97–1.00, P=0.02). ⭕In the large prospective cohort study of male US physicians (the Physicians’ Health Study), men drinking 1-3 cups/day had a lower risk of AF than non‐drinkers; >3 cups/day did not show stronger benefit. ⭕A more recent study using Mendelian randomisation found coffee consumption associated with a lower risk of AF (per‐cup OR ~0.89; 95%CI 0.84-0.93). ⭕In patients already with AF, moderate daily coffee consumption (2-3 cups/day) was associated with a lower hazard of major adverse cardiovascular events (MACE) compared to not‐daily consumption — in other words, no signal of harm and possible benefit. ⭕US guidelines/heart-health summaries now say: “Moderate coffee consumption (1-3 cups/day) is not linked to higher AF risk — may even be protective.” 🧩A recent randomised trial ⭕The new trial (called the DECAF trial — “Does Eliminating Coffee Avoid Fibrillation?”) involved ~200 patients with persistent AF or atrial flutter who underwent cardioversion. They were randomised to daily caffeinated coffee (at least 1 cup) vs abstinence from coffee/caffeine for 6 months. The coffee group had recurrence of AF/AFL in ~47% vs ~64% in the abstinence group (≈ ~39% relative reduction). ⭕The trial suggests that in this setting (post‐cardioversion) coffee consumption may reduce recurrence risk rather than increase it. Stay Consistent !!

A simple yet surprising clinical observation on Overactive Bladder Overactive bladder is caused by an abnormal entry of calcium ions into the bladder smooth muscle cells through pathways other than physiological ones. The increase in intracellular calcium triggers microcontractions that increase bladder tone, facilitate the opening of the first sphincter, and can lead to urinary leakage. Sensory afferents to the spinal cord and brain amplify signals from the bladder, generating pain, urgency, and incontinence, the latter resulting from incoordination. Under normal conditions, however, only a painless sense of fullness is perceived. beta blocker reduces adrenergic hyperactivity secondary to stress, decreases the release of norepinephrine and ATP, and raises the contraction threshold of the detrusor muscle. I have successfully used atenolol 25 mg/day on myself, as a sufferer of overactive bladder, and on five other patients, achieving complete remission of symptoms in all cases.

To Physiatrists - Post 2 of 4: Neurogenic Bladder & Bowel Management Your patients with neurogenic bladder and bowel face unpredictable, challenging incontinence—especially during intensive rehabilitation. Here's what the Curaco Carebidet does for these patients: **For Neurogenic Bladder:** ✓ Detects unpredictable voiding instantly ✓ Eliminates catheter-associated UTI risks ✓ Manages reflex incontinence automatically ✓ No timed voiding schedules interrupting therapy **For Neurogenic Bowel:** ✓ Handles unpredictable bowel movements immediately ✓ Manages both formed and loose stools ✓ Prevents perianal skin breakdown ✓ No bowel program timing conflicts with therapy **Perfect for patients with:** • Spinal cord injury (any level) • Multiple sclerosis • Parkinson's disease • Stroke with neurological deficits The system works seamlessly with rehabilitation schedules—no therapy interruptions, no complications derailing progress. FDA 510(k)-exempt | CMS-recognized | Billable E2001/A9286 👉 Follow for more rehabilitation solutions! 📅 See it in action: https://lnkd.in/gnjsUYzb Next: Patient scenarios →